Charles River Laboratories International, Inc. $CRL Position Lessened by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 30.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,900 shares of the medical research company’s stock after selling 5,100 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Charles River Laboratories International were worth $3,511,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in shares of Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after acquiring an additional 210,260 shares during the period. Bank of America Corp DE grew its holdings in Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after purchasing an additional 54,500 shares during the period. Amundi increased its stake in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares in the last quarter. Van Berkom & Associates Inc. increased its stake in Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after purchasing an additional 50,462 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Charles River Laboratories International by 2.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock valued at $51,099,000 after purchasing an additional 6,401 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CRL. Jefferies Financial Group increased their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. Evercore set a $330.00 target price on Charles River Laboratories International in a research report on Friday, September 25th. TD Cowen upped their price target on Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a research note on Monday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $302.33.

Charles River Laboratories International Stock Performance

CRL opened at $337.80 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company’s fifty day moving average price is $302.94 and its two-hundred day moving average price is $222.94. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $379.63. The company has a market cap of $16.13 billion, a price-to-earnings ratio of -69.65, a PEG ratio of 3.50 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James C. Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at $9,478,800. This trade represents a 51.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 118,169 shares of company stock worth $35,191,216 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.